Changes in the Availability of Medications for Opioid Use Disorder in Prisons and Jails in the United States During the COVID-19 Pandemic

Original research
by
Dadiomov, David et al

Release Date

2022

Geography

USA

Language of Resource

English

Full Text Available

No

Open Access / OK to Reproduce

No

Peer Reviewed

Yes

Objective

During the COVID-19 pandemic, federal agencies relaxed buprenorphine prescribing restrictions including for incarcerated individuals. The impact of COVID-19 on the supply of MOUD in U.S. prisons and jails is not known.

Findings/Key points

In prisons and jails, MOUD supply increased rapidly in early 2020 and then continued to increase during the COVID-19 pandemic.MOUD growth in prisons and jails was exclusively due to increases in buprenorphine/naloxone.

Design/methods

We used cross-sectional national monthly data.
doi.org

Keywords

Policy/Regulatory
Legal system/law enforcement
Substitution/OAT